Transparency Market Research (TMR), a pioneer in market intelligence, has recently published a report that captures the prudent trends and growth dynamics of global Diabetes Injection Pens Market. Since the time of their inception in the market, the product line has witnessed drastic evolution. This, predominantly, is due to the consistent research interventions by academic and scientific organizations, and pharmaceutical companies. The TMR report states that the technological interventions have kept the competition cut-throat. As the number of players with similar products increase, the pressure to enhance sales figures rises. This forces players in the global market for diabetic injection pens to roll out new or upgraded products.
As a result, companies are able to provide something new to the HCPs (healthcare providers), and the prescription loyalty is sustained. While investments to develop fresh products remain consistent, companies in the global diabetic injection pens market are also on the lookout for new patented technology. This way, they will be able to save time on research, and will directly focus on scaling up or testing. The key players in the global market for diabetic injection pens are Biocon Ltd., Eli Lilly and Company, Sanofi S.A., and Novo Nordisk A/S.
Request to View Sample of Report –
Speaking about the growth dynamics in the forecast period (2016-2024), TMR analysts predict that the global diabetic injection pens market would grow from US$ 4.9bn in 2015 to US$9.7 bn in 2024 at a competent 7.9% CAGR.
The TMR report elucidates the factors underlying growth in each segment in the global market for diabetic injection pens. The report discusses in detail the dynamics of segments like disposable pens, reusable pens, and more. Another pertinent aspect that affects business is geography, and this TMR report spells the regional analysis for the global diabetic pens market. It states that North America will be the leading region in terms of revenue in the coming years.
The idea behind diabetic injection pens is convenience. As companies begin to work out new ideas for their products, they realize the essence of monitoring consumer behavior consistently. And this helps players in the global diabetic injection pens market to focus on making products more use-friendly. By convenience, the products aim to make rendering an insulin shot a task for not more than 10 seconds. The idea is to eliminate dependence to deliver the medicine.